2025
Current practices for cohort reporting and statistical adjustment in studies from the STS Adult Cardiac Surgery Database
Mantaj P, Hameed I, Hirofuji A, Dell'Aquila M, Rahouma M, Abdalla S, Kennedy M, Gregg A, Rossi C, Soletti G, Falco G, Charlson M, Sandner S, Schwann T, Gaudino M. Current practices for cohort reporting and statistical adjustment in studies from the STS Adult Cardiac Surgery Database. The Annals Of Thoracic Surgery 2025 PMID: 40049382, DOI: 10.1016/j.athoracsur.2025.02.011.Peer-Reviewed Original ResearchAdult Cardiac Surgery DatabaseCardiac Surgery DatabaseParticipant User FileSTS ACSDValve surgerySurgery DatabaseThe Society of Thoracic Surgeons Adult Cardiac Surgery DatabaseSociety of Thoracic Surgeons Adult Cardiac Surgery DatabaseSTS Adult Cardiac Surgery DatabaseSurgical aortic valve replacementMitral valve surgeryTricuspid valve surgeryCoronary artery bypass graftingAortic valve replacementArtery bypass graftingStatistical adjustmentAortic surgeryValve replacementBaseline characteristicsBypass graftingCohort reportSurgerySenior authorMultivariate regressionPublished studiesApixaban to Prevent Covert Infarcts After Cryptogenic Stroke in Patients With Atrial Cardiopathy
Lansberg M, Wintermark M, Chen H, Howard G, Cassarly C, Pauls Q, Kemp S, Harris T, Krishnaiah B, Stanton R, Lyerly M, Miller B, Smith E, Tirschwell D, Sheth K, Kamel H, Longstreth W, Elkind M, Broderick J, Lazar R. Apixaban to Prevent Covert Infarcts After Cryptogenic Stroke in Patients With Atrial Cardiopathy. JAMA Neurology 2025, 82: 220-227. PMID: 39869342, PMCID: PMC11773411, DOI: 10.1001/jamaneurol.2024.4838.Peer-Reviewed Original ResearchConceptsCovert infarctsResearch magnetic resonance imagingCompletion of participationParticipant completionAtrial cardiopathyMain OutcomesParent studyRandomized clinical trialsPrimary outcomeFollow-up magnetic resonance imagingMagnetic resonance imagingParticipantsFollow-up periodRecurrent strokeStrokeIschemic strokeFollow-upBaseline characteristicsAncillary studiesCryptogenic strokeBaselineInsufficient qualityPreventionInfarctionIQRBASELINE PROGNOSTIC FACTORS OF BOWEL URGENCY IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB
Dubinsky M, Schreiber S, Matsuoka K, Jairath V, Al-Bawardy B, Pellanda P, Zhu B, Bleakman A, Redondo I, Owen C, Limdi J. BASELINE PROGNOSTIC FACTORS OF BOWEL URGENCY IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB. Inflammatory Bowel Diseases 2025, 31: s62-s63. DOI: 10.1093/ibd/izae282.147.Peer-Reviewed Original ResearchNumerical rating scalePain numerical rating scaleModified Mayo scoreMultivariate linear regression analysisInflammatory Bowel Disease QuestionnaireUnivariate analysisUlcerative colitisMayo scorePrognostic variablesAnti-IL-23p19 antibodyBaseline characteristics of patientsAnti-IL-23p19Linear regression analysisPhase 3 trialRegression analysisCharacteristics of patientsUrgency Numeric Rating ScaleBristol Stool ScaleMultivariate regression analysisPost hoc analysisUnivariate analysis of associationPrognostic factorsDisease extentBaseline characteristicsMirikizumabEffect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Adolescents With Cystic Fibrosis
Galderisi A, Weiss L, Besançon A, Stremler N, Reix P, Wizla N, Lustre A, Rames C, Tatopoulos A, Perisson C, Dalphin M, Troussier F, Houdouin V, Bessaci K, Cosson L, Gabsi A, Corvol H, Deneuville E, Storni V, Ramel S, Bui S, Heraud M, Remus N, Huet F, Scalbert M, Mely L, Gachelin E, Giannantonio M, Letierce A, Sahki D, Marguet C, Bonnel A, Sermet-Gaudelus I. Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Adolescents With Cystic Fibrosis. The Journal Of Clinical Endocrinology & Metabolism 2025, dgaf099. PMID: 39977216, DOI: 10.1210/clinem/dgaf099.Peer-Reviewed Original ResearchOral glucose tolerance testBaseline oral glucose tolerance testAbnormal glucose toleranceNormal glucose toleranceAbnormal glucose tolerance groupCystic fibrosisGlucose toleranceNormal glucose tolerance groupEffective CFTR modulatorsCF-related diabetesInsulin secretionImpaired fasting glucoseGlucose tolerance testImpaired glucose toleranceForced expiratory volumeBMIz-scoreCFTR modulatorsBaseline characteristicsRelated diabetesFasting glucoseTolerance testTherapeutic strategiesInsulin treatmentExpiratory volumeGlucose levelsWCN25-499 PATIENT BASELINE CHARACTERISTICS IN THE ONGOING PHASE 3 VISIONARY TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SIBEPRENLIMAB FOR IMMUNOGLOBULIN A NEPHROPATHY
Lafayette R, Trimarchi H, Barratt J, Carroll K, Tesar V, Zhang H, Suzuki Y, Liew A, Wong M, Shah L, Xia J, Fajaro C, Hafkin J, Perkovic V. WCN25-499 PATIENT BASELINE CHARACTERISTICS IN THE ONGOING PHASE 3 VISIONARY TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SIBEPRENLIMAB FOR IMMUNOGLOBULIN A NEPHROPATHY. Kidney International Reports 2025, 10: s158-s159. DOI: 10.1016/j.ekir.2024.11.328.Peer-Reviewed Original ResearchAficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy MAPLE-HCM Rationale, Study Design, and Baseline Characteristics
Garcia-Pavia P, Bilen O, Burroughs M, Costabel J, de Barros Correia E, Dybro A, Elliott P, Lakdawala N, Mann A, Nair A, Nassif M, Poulsen S, Reant P, Schulze P, Wang A, Berhane I, Heitner S, Jacoby D, Kupfer S, Malik F, Meng L, Sohn R, Wohltman A, Fifer M, Investigators M. Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy MAPLE-HCM Rationale, Study Design, and Baseline Characteristics. JACC Heart Failure 2025, 13: 346-357. PMID: 39909646, DOI: 10.1016/j.jchf.2024.11.011.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyStandard-of-careCardiac myosin inhibitorStandard-of-care medicationsBaseline characteristicsSymptomatic obstructive hypertrophic cardiomyopathyNondihydropyridine calcium channel blockersBaseline characteristics of patientsStandard-of-care drugsSecond-line therapyFirst-line therapyCalcium channel blockersCharacteristics of patientsImprove exercise capacityMyosin inhibitorFirst-lineBeta-blockersHypertrophic cardiomyopathyExercise capacityAlleviate symptomsPatientsAficamtenMedicationTherapyStudy designBiases in the performance of FRAX without BMD in predicting fracture risk in a multiethnic population with diabetes: the Diabetes and Aging Study
Jain R, Liu J, Grant R, Haider S, Huang E, Laiteerapong N, Lipska K, Lo J, Moffet H, Parker M, Karter A. Biases in the performance of FRAX without BMD in predicting fracture risk in a multiethnic population with diabetes: the Diabetes and Aging Study. Journal Of Bone And Mineral Research 2025, zjaf012. PMID: 39876767, DOI: 10.1093/jbmr/zjaf012.Peer-Reviewed Original ResearchPerformance of FRAXDuration of diabetesHip fractureFracture riskFollow-upExcess risk of fracturesFracture Risk Assessment ToolLong duration of diabetesStratify fracture riskHispanic womenFracture Risk CalculatorRisk of fractureHip fracture ratesPredicting fracture riskCalculator FRAXKaiser Permanente Northern California Diabetes RegistryOsteoporosis medicationsBaseline characteristicsDiabetes durationFracture ratesOlder patientsFRAXBMDPatientsBlack menP-565. A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) Study Design and Baseline Characteristics
Kumar P, Rolle C, Emu B, Henry Z, Martorell C, McKinnon J, Slim J, Cash R, Anstett K. P-565. A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) Study Design and Baseline Characteristics. Open Forum Infectious Diseases 2025, 12: ofae631.763. PMCID: PMC11778372, DOI: 10.1093/ofid/ofae631.763.Peer-Reviewed Original ResearchJournal of Antimicrobial ChemotherapyBaseline characteristicsViral loadMultidrug resistanceAntimicrobial chemotherapyCohort 2Maintenance of virologic suppressionHigher HIV viral loadClinical outcomes of patientsExposure to antiretroviralsGenotypic sensitivity scoreCD4 cell countHIV viral loadCD4 T cellsOutcomes of patientsLong-term efficacyRetrospective observational studyHigh viral loadLong-term useVirologic suppressionInfusion reactionsStudy designT cellsSafety profileClinical outcomesA randomized controlled trial comparing embryo vitrification with slush nitrogen to liquid nitrogen in women undergoing frozen embryo transfer: embryology and clinical outcomes
Klimczak A, Osman E, Esbert M, Yildirim R, Whitehead C, Herlihy N, Hanson B, Roberts L, Seli E, Scott R. A randomized controlled trial comparing embryo vitrification with slush nitrogen to liquid nitrogen in women undergoing frozen embryo transfer: embryology and clinical outcomes. Human Reproduction 2025, 40: 426-433. PMID: 39836897, DOI: 10.1093/humrep/deaf003.Peer-Reviewed Original ResearchFrozen embryo transferRandomized controlled trialsPregnancy outcomesIVF stimulationPre-clinical trialsEmbryo transferPregnancy rateFutility analysisPost-warming survival rateDATE OF FIRST PATIENT’S ENROLMENT:University-affiliated infertility centerClinical pregnancy rateEmbryo transfer outcomesSustained implantation ratesPreimplantation genetic testingFIRST PATIENT’S ENROLMENTBlastocyst biopsyEmbryological outcomesBlastocyst survivalEmbryo vitrificationHuman oocytesMiscarriage rateImplantation rateNo significant differenceBaseline characteristicsBaseline Characteristics and Risk Profiles of 1111 Patients With Primary Biliary Cholangitis (PBC) in Need of Second-Line Therapy
Hirschfield G, Kowdley K, Kremer A, Vierling J, Bowlus C, Levy C, Mayo M, Crittenden D, Standen M, Yang K, Choi Y, McWherter C. Baseline Characteristics and Risk Profiles of 1111 Patients With Primary Biliary Cholangitis (PBC) in Need of Second-Line Therapy. Zeitschrift Für Gastroenterologie 2025, 63: e19-e19. DOI: 10.1055/s-0044-1801043.Peer-Reviewed Original ResearchPrimary biliary cholangitisSecond-line therapyBiliary cholangitisBaseline characteristicsRisk profileCharacterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials
Senna M, Taylor S, Piraccini B, Shapiro J, Somani N, Jedynak J, Ogwu S, Buchanan A, Craiglow B, Ohyama M. Characterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials. SKIN The Journal Of Cutaneous Medicine 2025, 9: s522. DOI: 10.25251/skin.9.supp.522.Peer-Reviewed Original ResearchSeverity of Alopecia ToolLoss of responseSeverity of Alopecia Tool scoreBaricitinib 4 mgLost responseMaintenance treatmentAlopecia areataLong-term maintenance therapyYears of initial treatmentWeeks of maintenance treatmentBaseline disease characteristicsSevere alopecia areataPhase 3 trialYear of treatmentPost hoc analysisBaricitinib monotherapySevere AAMaintenance therapySALT scoreMaintained responseInitial treatmentBaseline characteristicsAdjunctive therapyTreatment responseCOVID-19 infection
2024
Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the USA
Inzucchi S, Tan X, Liang Y, Yedigarova L, Xie L, de Havenon A. Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the USA. Diabetes Therapy 2024, 16: 187-203. PMID: 39688779, PMCID: PMC11794941, DOI: 10.1007/s13300-024-01678-4.Peer-Reviewed Original ResearchHealth care resource utilizationAtherosclerotic cardiovascular diseaseDPP-4i usersDPP-4isGLP-1 RAsOnce-weekly semaglutideMedical costsType 2 diabetesDPP-4iDecreased risk of strokeRisk of cardiovascular outcomesCardiovascular eventsOnce-weekly GLP-1 RAsPeptide 1 receptor agonistsTotal medical costsDipeptidyl peptidase 4 inhibitorsOccurrence of cardiovascular eventsHigh-risk patientsRisk of strokeObservational cohort analysisData Mart DatabaseOutpatient visitsDecreased riskSemaglutide treatmentBaseline characteristicsThe Incidence and Significance of Iliac Vein Stenosis in Patients with Deep Vein Thrombosis
Ali S, Chan S, Brahmandam A, Xu Y, Deng Y, Elbadawy A, Lee A, Ochoa Chaar C. The Incidence and Significance of Iliac Vein Stenosis in Patients with Deep Vein Thrombosis. Annals Of Vascular Surgery 2024, 111: 310-318. PMID: 39617297, DOI: 10.1016/j.avsg.2024.11.016.Peer-Reviewed Original ResearchIliac vein stenosisIpsilateral DVT recurrenceCross-sectional imagingDVT recurrenceVein stenosisMedical records of consecutive adult patientsRecords of consecutive adult patientsSubgroup analysisPrevention of pulmonary embolismDevelopment of DVTConsecutive adult patientsIncidence of PEDeep vein thrombosisGroup of patientsLower extremity DVTRecurrent DVTPulmonary embolismVein thrombosisBaseline characteristicsRetrospective studyAdult patientsDVTPatientsElectronic medical recordsStatistical significanceRacial and Ethnic Disparities in the Use and Outcomes With WATCHMAN FLX: A SURPASS Analysis of the NCDR Left Atrial Appendage Occlusion Registry
Alli O, Garg J, Boursiquot B, Kapadia S, Yeh R, Price M, Piccini J, Nair D, Hsu J, Gibson D, Allocco D, Christen T, Sutton B, Freeman J. Racial and Ethnic Disparities in the Use and Outcomes With WATCHMAN FLX: A SURPASS Analysis of the NCDR Left Atrial Appendage Occlusion Registry. Journal Of The American Heart Association 2024, 13: e036406. PMID: 39575715, PMCID: PMC11681556, DOI: 10.1161/jaha.124.036406.Peer-Reviewed Original ResearchLeft atrial appendage occlusionWatchman FLX implantationBlack patientsHispanic patientsOral anticoagulantsProcedural successRates of 1-year deathWhite patientsAlternative to oral anticoagulationRate of procedural successEthnic minority groupsEthnic minority individualsRate of deathSignificant bleedingWatchman FLXMinority individualsAppendage occlusionAntiplatelet therapyBaseline characteristicsAtrial fibrillationAnalyses assessed differencesMinority groupsPatientsStroke preventionBleedingPonatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison
Garcia-Gutierrez V, Huang F, Ashaye A, Dalal M, Laliman-Khara V, Breccia M, Rutherford M, Moradian H, Patos P, Jabbour E. Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison. Frontiers In Oncology 2024, 14: 1455378. PMID: 39634261, PMCID: PMC11615674, DOI: 10.3389/fonc.2024.1455378.Peer-Reviewed Original ResearchMatching-adjusted indirect comparisonChronic-phase chronic myeloid leukemiaChronic myeloid leukemiaT315I mutationCP-CMLMyeloid leukemiaTyrosine kinase inhibitor therapyIndirect comparisonsResponse rateBaseline responsesSecond-generation TKIsT315I mutation statusKinase inhibitor therapyThird-line therapyMedical literature databasesInhibitor therapyMutation subgroupsMutation statusPatient-level dataEfficacy outcomesBaseline characteristicsMMR rateProportion Z testClinical trialsCumulative rateSorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors
Costa P, Arora A, Fernandez Y, Yi I, Bakkila B, Tan H, Coelho P, Campoverde L, Hardy N, Bialick S, Freire A, D’Amato G, Chang Y, Mesenger J, Subhawong T, Haims A, Hurwitz M, Olino K, Turaga K, Deshpande H, Trent J. Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors. Cancer 2024, 131: e35647. PMID: 39543805, DOI: 10.1002/cncr.35647.Peer-Reviewed Original ResearchProgression-free survivalAnthracycline-containing regimensAnthracycline-based therapyDesmoid tumorsAdverse eventsOne-year progression-free survivalMulti-institutional retrospective analysisAnthracycline-containing regimenCommon grade 1Desmoid tumor patientsGrade 3 eventsAnthracycline-based chemotherapyHand-foot syndromeSecondary end pointsActivity of sorafenibProgressive desmoid tumorsYear of treatmentMedian TTRBaseline characteristicsTumor patientsLocal invasionTreatment responseSorafenibAnthracyclinesEnd pointsThe Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Shah K, El Kettani M, Narra R, Mims A, Coltoff A, Medawar G, Hisrich B, Shallis R, Hunter C, Kota V, Othman T, Jonas B, Desai S, Sacchi de Camargo Correia G, Patel A, Duvall A, Palmisiano N, Curran E, Omer Z, Advani A, Atallah E, Litzow M, Badar T. The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood 2024, 144: 4184-4184. DOI: 10.1182/blood-2024-205812.Peer-Reviewed Original ResearchCNS relapseCentral nervous system involvementPh+ acute lymphoblastic leukemiaRelapse free survivalTyrosine kinase inhibitorsAcute lymphoblastic leukemiaIncidence of CNS relapseMedian relapse free survivalCentral nervous systemCNS diseaseOverall survivalAllo-HCTIntrathecal chemotherapyWhite blood cellsIntensive chemotherapyPost-relapseT315I mutationBaseline characteristicsMedian time to CNS relapseAllogeneic stem cell transplantationAssociated with significant toxicityIncidence of CNS diseaseMedian white blood cellAdequate CNS prophylaxisCentral nervous system penetrationPre-emptive use of glucose 5% as the standard drug solvent reduces hypernatremia in critically ill patients
Hardenberg J, Kunz J, Rubarth K, Mittermaier M, Pigorsch M, Balzer F, Witzenrath M, Hinz R, Körner R, Eckardt K, Knauf F, Hinrichs C, Enghard P. Pre-emptive use of glucose 5% as the standard drug solvent reduces hypernatremia in critically ill patients. Clinical Kidney Journal 2024, 17: sfae328. PMID: 39582778, PMCID: PMC11584513, DOI: 10.1093/ckj/sfae328.Peer-Reviewed Original ResearchGlucose 5% solutionGlucose 5%Severe hypernatremiaDrug diluentDrug solventSodium concentrationAssociated with increased mortalityResults Baseline characteristicsAdult COVID-19 patientsRetrospective before-and-after studyCritically ill patientsIntensive care unitPre-emptive usePrevalence of hypernatremiaStudy intensive care unitVenous blood gasesLength of stayCOVID-19 patientsBaseline characteristicsClinical outcomesICU admissionHypernatremiaMedical ICUCare unitBlood gasesFactors Associated With Surgical Management in Gallbladder Cancer—A Surveillance, Epidemiology, and End Results Medicare–Based Study
Romatoski K, Chung S, Sawhney V, Papageorge M, de Geus S, Ng S, Kenzik K, Tseng J, Sachs T. Factors Associated With Surgical Management in Gallbladder Cancer—A Surveillance, Epidemiology, and End Results Medicare–Based Study. Journal Of Surgical Research 2024, 304: 9-18. PMID: 39481161, DOI: 10.1016/j.jss.2024.09.084.Peer-Reviewed Original ResearchGallbladder cancer patientsGallbladder cancerOncologic resectionStage T1bComplete resectionOverall survivalSurgical oncologistsGeneral surgeonsChi-square and Wilcoxon rank-sum testsOverall survival outcomesNonacademic hospitalsWilcoxon rank sum testRank sum testResection rateSurgical managementSurvival outcomesImproved survivalBaseline characteristicsResectionSEER-MedicarePatient factorsAcademic centersPatientsCCI patientsFrail statusLong-term outcomes of elective endovascular vs open repair of popliteal artery aneurysms in the VISION database
Satam K, Brahmandam A, Zheng X, Mao J, Goodney P, Ochoa Chaar C. Long-term outcomes of elective endovascular vs open repair of popliteal artery aneurysms in the VISION database. Journal Of Vascular Surgery 2024, 81: 672-681.e2. PMID: 39454844, DOI: 10.1016/j.jvs.2024.10.026.Peer-Reviewed Original ResearchPopliteal artery aneurysm repairGreat saphenous veinLong-term outcomesVascular Quality InitiativeAneurysm repairAssociated with increased survivalShort hospital length of stayGreat saphenous vein bypassHospital length of stayRandomized multicenter studyCox proportional hazards regressionKaplan-Meier curvesAssociated with lower mortalityPopliteal aneurysm repairPopliteal artery aneurysmPeripheral vascular interventionsProportional hazards regressionLength of stayP2Y12 inhibitorsBaseline characteristicsMulticenter studyEndovascular therapyArtery aneurysmPropensity-matchedSubgroup analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply